PO.CH02.02 · 化学
使用HCR™ Gold和MoxiePlex在FFPE肿瘤中对临床相关的蛋白和RNA靶标进行9通道空间共检测
9-channel spatial co-detection of clinically relevant protein and RNA targets in FFPE tumors with HCR™ Gold and MoxiePlex
该海报暂无可下载的资料
AACR 官方页面
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:FFPE肿瘤中蛋白和RNA的高重数空间分析对于表征肿瘤-免疫相互作用日益重要,但现有方法往往将探索局限于预定义的抗体面板、剧烈的剥脱/洗脱步骤,以及有损样本和靶标完整性、使检测开发和验证繁重的迭代循环。由HiFi编码器赋能的HCR™ Gold IF支持使用未修饰的、用户自备的一抗进行无酶荧光检测,并与HCR™ Gold RNA-FISH运行在同一扩增平台上。结合Hamamatsu MoxiePlex多光谱组织成像平台——该平台无需循环染色即可对7-9重面板进行全玻片单轮成像——这一工作流程为FFPE标本中灵活的7-9重蛋白和RNA共检测提供了一条实用途径。
方法:FFPE人肿瘤切片使用HCR™ Gold IF进行染色,采用经编码的、临床验证的一抗以及HCR™ HiFi探针。在MoxiePlex上测试了两种并行的多重配置:1. 7重面板:DAPI、425、488、546、594、700、750;2. 9重面板:DAPI、425、488、514、546、594、633、700、750。面板纳入了针对癌症相关蛋白(如pan-CK、Ki-67、PD-L1、CD8、CD68)和代表肿瘤及免疫生物学的RNA靶标(如EPCAM、CXCL9、CD274)的抗体。对每种荧光染料-靶标组合,均生成单染参考玻片以确定曝光设置、验证滤光片性能,并量化光谱渗漏以实现光谱解混。多重玻片在单次采集轮次中成像,数据从信号强度、通道串扰、预期生物学定位以及与单染参考的一致性方面进行评估。光谱解混在采集后作为成像过程的一部分对全玻片图像自动进行。
结果:HCR™ Gold IF和HCR™ Gold RNA-FISH产生了明亮、稳健的信号,并保持了组织结构。在全玻片多重成像中,蛋白和RNA靶标定位于预期的肿瘤和基质区域,突显了肿瘤微环境中的免疫浸润,其表达与单染参考模式高度吻合。MoxiePlex平台提供了一致的全玻片成像性能,采集设置可重复,适合常规的7-9重扫描。
结论:HCR™ Gold IF和HCR™ Gold RNA-FISH可在MoxiePlex上以单轮工作流程结合使用,实现对FFPE组织中临床相关蛋白和RNA靶标高达9重的成像。该方法避免了剥脱或光漂白,保持了与经验证抗体和标准滤光片组的兼容性,并为转化和临床研究中灵活的7-9重空间检测提供了一条实用途径。
查看英文原文 English abstract
Background: High-plex spatial profiling of protein & RNA in FFPE tumors is increasingly important for characterizing tumor-immune interactions, but existing methods often limit exploration to predefined antibody panels, harsh stripping/eluting steps, and iterative cycles that compromise sample and target integrity and make assay development and validation burdensome. HCR™ Gold IF, enabled by the HiFi Encoder, supports enzyme-free fluorescent detection using unmodified, user-supplied primary antibodies and operates on the same amplification platform as HCR™ Gold RNA-FISH. Combined with the Hamamatsu MoxiePlex multispectral tissue imaging platform, which enables whole-slide single-round imaging of 7-9-plex panels without the need for cyclic-staining, this workflow offers a practical route to flexible, 7-9-plex protein and RNA co-detection in FFPE specimens.
Methods: FFPE human tumor sections were stained with HCR™ Gold IF using encoded, clinically validated primary antibodies alongside HCR™ HiFi Probes. Two parallel multiplex configurations were tested on the MoxiePlex:1. 7-plex panel: DAPI, 425, 488, 546, 594, 700, 7502. 9-plex panel: DAPI, 425, 488, 514, 546, 594, 633, 700, 750Panels incorporated antibodies specific to cancer-relevant proteins (e.g., pan-CK, Ki-67, PD-L1, CD8, CD68) & RNA targets representing tumor and immune biology (e.g., EPCAM, CXCL9, CD274). For each fluorophore-target combination, single-stain reference slides were generated to establish exposure settings, verify filter performance, and quantify spectral bleed-through to enable spectral unmxing. Multiplex slides were imaged in a single acquisition round, and data were evaluated for signal intensity, channel crosstalk, expected biological localization, and concordance with single-stain references. Spectral unmixing was carried out automatically for the whole- slide image, following acquisition, as part of the imaging process.
Results: HCR™ Gold IF & HCR™ Gold RNA-FISH produced bright, robust signals with preserved tissue architecture. In whole- slide multiplex imaging, protein and RNA targets localized to expected tumor and stroma regions highlighting immune infliltration in the tumor microenvironment, the expression of which. closely matched single-stain reference patterns. The MoxiePlex platform delivered consistent, whole-slide imaging performance with reproducible acquisition settings appropriate for routine 7-9-plex scanning.
Conclusions: HCR™ Gold IF & HCR™ Gold RNA-FISH can be combined in a single-round workflow on the MoxiePlex to achieve up to 9-plex imaging of clinically relevant protein and RNA targets in FFPE tissue. This approach avoids stripping or photobleaching, maintains compatibility with validated antibodies and standard filter sets, and provides a practical path for flexible, 7-9-plex spatial assays in translational and clinical research.
利益披露 Disclosure
W. Yang, None..
R. Chen, None..
H. Choi, None..
A. Acharya, None..
M. Singh, None..
Q. Vu, None.